Intellectual Product – Page 3

Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies

1 week ago talkbio0Tagged Administration occupational activities, Albert, Bourla, chain concerns, Evaluation, Investments, Manufacturing, National Security, pharmaceutical tariffs, Policy, Sectioning technique, TNFRSF19 gene, Transplant Registry Unified Management Program

Pharmaceutical tariffs, Section 232 investigation, Albert Bourla, national security, trade policy, manufacturing investments, Trump administration, supply chain concerns

Octagon Therapeutics Ceases Operations Due to R&D Challenges and Unresolved Biology Questions

1 week ago talkbio0Tagged Autoimmune Diseases, B cell immunomodulator program, biology (field), Flatulence, Nordisk alliance, OCT50, Programs - Publication Format

Autoimmune disease biotech, B cell immunomodulator program, OCT50 program, Novo Nordisk alliance, Winding down operations, Unresolved biology challenges

Biohaven, after setbacks, sees shares jump with Oberland Capital funding agreement worth up to $600M

1 week ago talkbio0Tagged Approved, Ataxia, Spinocerebellar, Capital, Investments, non-dilutive, Note (document), secured, United States Food and Drug Administration

Biohaven, Oberland Capital, $600 million investment, troriluzole, spinocerebellar ataxia (SCA), non-dilutive funding, FDA approval, senior secured notes

J&J reports durability data for bladder cancer ‘pretzel’ drug after FDA filing

2 weeks ago talkbio0Tagged Malignant neoplasm of urinary bladder, TAR 200, United States Food and Drug Administration, Urinary Bladder

Urinary Bladder, TAR 200, United States Food and Drug Administration, Malignant neoplasm of urinary bladder

Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects

2 weeks ago talkbio0Tagged 32%, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, CAR-T, Cell Therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, Neoplasms, Reindeer, Staff, United States Food and Drug Administration

Reindeer, CAR-T, Staff, Neoplasms, Cell Therapy, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, United States Food and Drug Administration, 32%